Description

This issue of Vital Signs, released on January 18, 2010, provides a strategic overview of trends in MD, nurse and cancer patient feedback about drug delivery and treatment in oncology, as well as the value sought from this area from multiple facets of the pharma industry. Additionally, a company spotlight is provided for Cure DM, a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin therapy. Reimbursement and regulatory news from the FDA is also provided for the week of December 28, 2009.